Optimal number and sizes of the doses in fractionated radiotherapy according to the LQ model

被引:4
作者
Bruni, C. [1 ]
Conte, F. [1 ]
Papa, F. [1 ]
Sinisgalli, C. [1 ]
机构
[1] CNR, Ist Anal Sistemi & Informat A Ruberti, Via Taurini 19, I-00185 Rome, Italy
来源
MATHEMATICAL MEDICINE AND BIOLOGY-A JOURNAL OF THE IMA | 2019年 / 36卷 / 01期
关键词
non-linear programming; linear-quadratic LQ model; cancer radiotherapy; LINEAR-QUADRATIC MODEL; PROSTATE-CANCER; ACCELERATED RADIOTHERAPY; RADIATION-THERAPY; ALPHA/BETA RATIO; NORMAL TISSUE; TUMOR REPOPULATION; IN-VIVO; TIME; SCHEDULES;
D O I
10.1093/imammb/dqx020
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We address a non-linear programming problem to find the optimal scheme of dose fractionation in cancer radiotherapy. Using the LQ model to represent the response to radiation of tumour and normal tissues, we formulate a constrained non-linear optimization problem in terms of the variables number and sizes of the dose fractions. Quadratic constraints are imposed to guarantee that the damages to the early and late responding normal tissues do not exceed assigned tolerable levels. Linear constraints are set to limit the size of the daily doses. The optimal solutions are found in two steps: i) analytical determination of the optimal sizes of the fractional doses for a fixed, but arbitrary number of fractions n; ii) numerical simulation of a sequence of the previous optima for n increasing, and for specific tumour classes. We prove the existence of a finite upper bound for the optimal number of fractions. So, the optimum with respect to n is found by means of a finite number of comparisons amongst the optimal values of the objective function at the first step. In the numerical simulations, the radiosensitivity and repopulation parameters of the normal tissue are fixed, while we investigate the behaviour of the optimal solution for wide variations of the tumour parameters, relating our optima to real clinical protocols. We recognize that the optimality of hypo or equi-fractionated treatment schemes depends on the value of the tumour radiosensitivity ratio compared to the normal tissue radiosensitivity. Fast growing, radioresistant tumours may require particularly short optimal treatments.
引用
收藏
页码:1 / 53
页数:53
相关论文
共 85 条
[21]  
Dawson A., 2006, Computational and Mathematical Methods in Medicine, V7, P121
[22]   Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial [J].
Dearnaley, David ;
Syndikus, Isabel ;
Mossop, Helen ;
Khoo, Vincent ;
Birtle, Alison ;
Bloomfield, David ;
Graham, John ;
Kirkbride, Peter ;
Logue, John ;
Malik, Zafar ;
Money-Kyrle, Julian ;
O'Sullivan, Joe M. ;
Panades, Miguel ;
Parker, Chris ;
Patterson, Helen ;
Scrase, Christopher ;
Staffurth, John ;
Stockdale, Andrew ;
Tremlett, Jean ;
Bidmead, Margaret ;
Mayles, Helen ;
Naismith, Olivia ;
South, Chris ;
Gao, Annie ;
Cruickshank, Clare ;
Hassan, Shama ;
Pugh, Julia ;
Griffin, Clare ;
Hall, Emma .
LANCET ONCOLOGY, 2016, 17 (08) :1047-1060
[23]  
Dionysiou DD, 2004, J THEOR BIOL, V230, P1, DOI 10.1016/j.jtbi.2004.03.024
[24]  
Duchting W, 1992, Strahlenther Onkol, V168, P354
[25]   MODELING OF RADIOGENIC RESPONSES INDUCED BY FRACTIONATED-IRRADIATION IN MALIGNANT AND NORMAL TISSUE [J].
DUCHTING, W ;
GINSBERG, T ;
ULMER, W .
STEM CELLS, 1995, 13 :301-306
[26]   Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine [J].
Dulaney, Caleb R. ;
Osula, Daniel O. ;
Yang, Eddy S. ;
Rais-Bahrami, Soroush .
PROSTATE CANCER, 2016, 2016
[27]   Repopulation of interacting tumor cells during fractionated radiotherapy: Stochastic modeling of the tumor control probability [J].
Fakir, Hatim ;
Hlatky, Lynn ;
Li, Huamin ;
Sachs, Rainer .
MEDICAL PHYSICS, 2013, 40 (12)
[28]   Optimum overall times II: Extended modelling for head and neck radiotherapy [J].
Fowler, J. F. .
CLINICAL ONCOLOGY, 2008, 20 (02) :113-126
[29]   Is there an optimum overall time for head and neck radiotherapy? A review, with new modelling [J].
Fowler, J. F. .
CLINICAL ONCOLOGY, 2007, 19 (01) :8-22
[30]   21 years of Biologically Effective Dose [J].
Fowler, J. F. .
BRITISH JOURNAL OF RADIOLOGY, 2010, 83 (991) :554-568